IP Library Patent Application 16129589
Patent Application
App. No. 16/129,589

ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
16/129,589
Abstract

Provided herein is a pharmaceutical composition comprising at least one isoflavonoid. Also provided herein are methods of treating cancer, sensitizing cancer cells, and inducing apoptosis in cancer cells by administering such compositions.

Claims (11)

1 .- 15 . (canceled)

16 . A compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

17 . A kit comprising a compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

and

a sealable, plastic infusion bag.

18 . A method of treating cancer in an individual in need of cancer therapy, the method comprising administering to the individual a compound that is cis-3-(4-hydroxyphenyl)-4-(4-hydroxyphenyl)-8-methylchroman-7-ol.

19 . The method of claim 18 , wherein the compound increases or induces sensitivity of the cancer to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

20 . The method of claim 18 , wherein the cancer has lost sensitivity to a chemotherapeutic agent, anti-cancer agent, or radiation therapy.

21 . The method of claim 18 , wherein said cancer is selected from the group consisting of bladder cancer, breast cancer, colon cancer, rectal cancer, endometrial cancer, kidney cancer, leukemia, lung cancer, melanoma, non-Hodgkin lymphoma, ovarian cancer, pancreatic cancer, prostate cancer, thyroid cancer, and cancers of the brain.

22 . The method of claim 18 , wherein said cancer is human breast cancer or ovarian cancer.

23 . The method of claim 18 , wherein the method further comprises administering an additional anti-cancer agent selected from the group consisting of cisplatin, carboplatin, paclitaxel, gemcitabine, doxorubicin, epirubicin, cyclophosphamide, capecitabine, 5-fluorouracil, vinorelbine, trastuzumab, or bevacizumab.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 12, 2018
From: MORENO, OFIR; JEOFFREYS, GEORGE; JOHNSON, ALISON; HEATON, ANDREW
To: MARSHALL EDWARDS, INC.
Reel/Frame 046858/0026 →
MERGER AND CHANGE OF NAME Recorded Sep 12, 2018
From: MEI PHARMA, INC.; MARSHALL EDWARDS, INC.
To: MEI PHARMA, INC.
Reel/Frame 046858/0192 →